Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CML-VAX B2/B3 Vaccine in CML Patients with Minimal Residual Disease
NCT00267085Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2005
- Primary completion
- Jul 2008
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CML-VAX B2 and BCR-ABL multipeptide vaccine in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response: One Log Decrease in BCR-ABL at 12 months. Started Dec 2005; status: completed.
02
Drugs
CML-VAX B2BCR-ABL multipeptide vaccine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00267085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267085.